HLS Therapeutics Inc continues to navigate a challenging market environment, with recent financial results reflecting mixed performance.
This week, HLS Therapeutics Inc (HLS.TO) has seen its stock price decline by 2.76%, closing at C$3.94 on Thursday. The company recently reported its Q2 2026 financial results, showcasing a modest revenue increase amid ongoing operational changes. Let's delve into the details surrounding HLS Therapeutics and its stock performance.
Investor takeaway: Investors should keep an eye on HLS Therapeutics' growth trajectory and operational adjustments, particularly in light of its recent financial results and ongoing initiatives.
Advertisement
HLS Therapeutics Inc
HLS.TO
HLS.TO
HLS Therapeutics Inc
WealthAwesomeMarket cap
$119.72M
52W high
$5.76
52W low
$3.71
1W change
-2.76%
Beta
0.86
Analyst Price Targets
Based on analyst covering HLS
Wall Street analysts forecast HLS stock price to rise 88.5% over the next 12 months.
Consensus
BullishBased on avg. target vs last close (formal rating unavailable for Canadian listings)
Avg. Target
C$7.30
+88.5% Upside
Current Price
C$3.87
Last close
Analyst ratings and price targets are updated periodically. Not financial advice.
Wealth Awesome Price Forecast
WA ModelStatistical 90-day price range based on HLS's historical volatility
30-Day Vol
25.7%
Annualized
90-Day Vol
24.6%
Annualized
Trend (90d)
-50.0%
Annualized drift
90d Mean
C$3.24
Expected price
| Horizon | Expected | 68% Range (1ฯ) |
|---|---|---|
| 30 trading days | C$3.65 | C$3.34 โ C$3.98 |
| 60 trading days | C$3.44 | C$3.03 โ C$3.89 |
| 90 trading days | C$3.24 | C$2.78 โ C$3.77 |
Methodology: Range is calculated using 30-day realized volatility via geometric Brownian motion (log-normal model). 68% band = ยฑ1ฯ, 95% band = ยฑ2ฯ. This is a statistical model, not a prediction. Past volatility does not guarantee future results. Not financial advice.
Advertisement
HLS Therapeutics Reports 3.5% Revenue Growth in Q2 2026
The growth in revenue is primarily attributed to a 25% increase in net sales from the cardiovascular portfolio, indicating a positive trend in product demand.
Bull case
HLS has shown strong growth in its cardiovascular portfolio and has secured reimbursement for key products. This could lead to increased revenue in the future.
Bear case
Despite growth in certain areas, HLS faces challenges with profit margins and overall stock performance, which may concern investors.
Recent Price Action
HLS Therapeutics Inc has experienced a decline of 2.76% over the past week, with the stock closing at C$3.94 on Thursday. The stock has faced a broader downward trend with a year-to-date decrease of 20.21%. Investors may be reflecting on the company's financial results and market positioning as they consider their next steps.
Company News and Financial Results
Advertisement
The company recently announced its Q2 2026 financial results, reporting a revenue of $14.7 million, marking a 3.5% increase year-over-year. Notably, the cardiovascular portfolio saw a significant 25% growth in net sales. Additionally, HLS has been proactive in securing reimbursement for its product NILEMDOโข with major private payers in Canada, further supporting its revenue growth. Despite these positive developments, the company continues to grapple with a profit margin of -15.2% and a negative return on equity of -14.1%.
Technical Picture
From a technical perspective, HLS Therapeutics is trading below its 50-day moving average of C$4.20 and its 200-day moving average of C$4.56, indicating a bearish trend. The stock has a beta of 0.86, suggesting lower volatility compared to the market. The current 52-week range for HLS is between C$3.71 and C$5.76, with the stock currently at approximately 11% of its range. Recent trading volume has been lower than average, with 59,900 shares traded compared to a 20-day average of 61,031 shares.
Insider Activity
No recent insider activity has been reported for HLS Therapeutics, indicating a lack of significant insider trading movements that could influence investor sentiment.
Price Action Summary
HLS Therapeutics Inc closed at C$3.94 on Thursday, reflecting a 1D decline of 0.77%. As the company continues to navigate its financial landscape, investors may want to monitor future developments closely.
Best next step
Keep exploring this topic
If you want to go deeper, these are the most useful follow-up pages and tools for this topic.
Broker comparison
Best trading platforms in Canada
Compare $0-commission brokers before you act on a ticker story.
Safe cash
Best GIC rates in Canada
If the story makes you want to de-risk, compare guaranteed rates next.
HISA roundup
Best high-interest savings accounts
Keep dry powder in a no-fee savings account instead of chequing.
TFSA room
Check TFSA contribution room
Shelter the next contribution before you buy.
Advertisement
Wealth Awesome
Timely coverage of Canadian stocks, earnings, dividends, and market movers for DIY investors. Stories are checked against exchange data and public filings.
View Full Profile โโ Reviewed by Certified Financial Professionals
This content has been reviewed by CFAยฎ charterholders and Certified Financial Planners (CFPยฎ) with over a decade of experience in Canadian financial markets. All information is fact-checked against official Canadian sources and regulations.
Why these credentials matter: CFAยฎ charterholders complete 900+ hours of rigorous study in investment analysis and ethics. CFPยฎ professionals are held to the highest standards of financial planning competency and fiduciary duty in Canada.
โ ๏ธ Professional Disclaimer
This content is for educational purposes only and should not be considered personalized financial advice. While our team brings professional expertise, individual circumstances vary. For personalized guidance, consult with a qualified financial advisor, tax professional, or mortgage specialist.
